Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 2,756 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: HIV-1-infection
Interventions: GS-1219, BVY, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
Interventions: Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 24 Years
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: St. Petersburg, Florida • Baltimore, Maryland • New York, New York + 2 more

Conditions: Obesity, Healthy
Interventions: PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan); Diagnostic Test · Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stroke
Interventions: Transcranial direct current stimulation (high- definition); Device
Lead sponsor: Carle Foundation Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Erectile Dysfunction, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Radiation Therapy, Erectile Dysfunction Due to General Medical Condition, Erectile Dysfunction Due to Arterial Insufficiency
Interventions: Storz Duolith Low-Intensity Shockwave Therapy; Device
Lead sponsor: University of Virginia; Other
Eligibility: 30 Years to 80 Years · Male only
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Sedentary Lifestyle, Hyperinsulinemia, Glucose Tolerance Impaired, Low-density-lipoprotein-type, Aging Problems, Lipid Metabolism Disorders, Inactivity, Physical, Metabolic Disorder, Glucose
Interventions: Muscular Exercise; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prodromal Schizophrenia
Interventions: Neurofeedback processing speed training, Active control; Behavioral
Lead sponsor: Hartford Hospital; Other
Eligibility: 12 Years to 25 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Hartford, Connecticut

Conditions: Autoimmune Encephalitis, Encephalitis
Interventions: Inebilizumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 12 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more

Conditions: Healthy
Interventions: Physical Activity Level; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 35 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions: Nicotinamide, Standard Glaucoma Therapy; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stress, Emotional
Interventions: tailored MBI (.b), attention control condition; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 25 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peanut Allergies
Interventions: MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle); Drug
Lead sponsor: Mabylon AG; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more

Conditions: Hypertensive Disorder of Pregnancy
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 66 participants
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Ocular Hypertension, Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 19 Years to 99 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Atherosclerosis, Metabolic Syndrome
Interventions: Prolonged sitting with exercise, Active walking with exercise.; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Parkinson Disease
Interventions: Exercise; Behavioral
Lead sponsor: Arkansas Colleges of Health Education; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fort Smith, Arkansas

Conditions: Metastatic Melanoma, Metastasis to Brain
Interventions: Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Standard of Care Craniotomy; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Tampa, Florida • Houston, Texas

Conditions: Burnout, Professional, Resilience, Psychological
Interventions: Three Good Things, Gratitude, Random Acts of Kindess, Awe, 1 Good Chat; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2,650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Palo Alto, California • Stanford, California • Boston, Massachusetts + 5 more

Conditions: Alcohol Consumption, Alcoholic Intoxication, Alcoholism, Alcohol-induced Disorders
Interventions: BASICS counseling, naltrexone, placebo naltrexone; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Severe Hypertriglyceridemia
Interventions: K-877, Fenofibrate, Placebo (for K-877); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 129
States / cities: Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more

Conditions: Aging, Functional Recovery, Skilled Nursing Facility, Medically Complex, Deconditioning
Interventions: i-STRONGER, Usual Care; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 120 Years
Enrollment: 4,383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Aurora, Colorado • Frisco, Texas

Conditions: Spastic Cerebral Palsy
Interventions: Selective movement of individual lower limb joints, Knee joint strengthening at high velocities, Ankle controlled gaming, Functional activities based on child and parental goals, Sensori-motor exercises; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 5 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neuroblastoma
Interventions: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study of GS-1219 in Participants With HIV-1

Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings

Sympathetic Activation in Obesity

Determine the Effect of Targeted High-definition Transcranial Direct Current Stimulation (tDCS) on Reducing Post-stroke Upper Limb Motor Impairments

Low Intensity Shockwave Therapy for Erectile Dysfunction

Developing a Physiological Understanding of High Duration Activity

Neurofeedback Training for High Risk Psychosis

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

Examining the Feasibility and Acceptability of a Tailored Version of a Mindfulness-Based Intervention (MBI) Among Youth Experiencing Homelessness (YEH)

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

Platelets in Pregnancy

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Prolonged Sitting on Responses to Short-Term Exercise Training

Support + High Intensity Functional Training for Parkinson's

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Web-based Implementation for the Science of Enhancing Resilience Study

Naltrexone for Heavy Drinking in Young Adults

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Advancing Rehabilitation Paradigms for Older Adults in Skilled Nursing Facilities

A Physical Therapy Program Targeting Lower Extremity Selective Motor Control in Children With Spastic Cerebral Palsy

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma